Physician profile
Peter Michael Grondziowski
NPI 1447250469
$142,961.42
in general payments reported to CMS, 2019-2025
28 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $19K · 2021: $17K · 2022: $40K · 2023: $7,172 · 2024: $882 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,744 · Food and Beverage: $3,448 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,743.75 |
| Food and Beverage | $3,448.36 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134,990.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,268.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $729.44 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $724.83 | 2019-2025 | |
| Amgen INC. | $704.70 | 2020-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.75 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $638.71 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $637.48 | 2021-2025 | |
| Abbvie INC. | $528.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $475.42 | 2019-2024 | Farxiga |
| Tandem Diabetes Care, INC. | $412.36 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $355.10 | 2021-2025 | Unithroid |
| Corcept Therapeutics | $161.94 | 2019-2024 | Korlym |
| Madrigal Pharmaceuticals | $138.67 | 2025 | Rezdiffra |
| Mannkind Corporation | $84.83 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $57.96 | 2023-2025 | Yorvipath |
| Rhythm Pharmaceuticals, INC. | $53.96 | 2022-2023 | Imcivree |
| Xeris Pharmaceuticals, INC. | $50.72 | 2021-2024 | Gvoke Hypopen |
| Ibsa Pharma INC. | $43.01 | 2021-2023 | Tirosint, Licart |
| Pfizer INC. | $42.81 | 2022-2024 | |
| Abbott Laboratories | $34.91 | 2022-2023 | Freestyle Libre 3 |
| Allergan, INC. | $30.76 | 2019-2022 | |
| Cequr Corporation | $29.25 | 2022 | |
| Sun Pharmaceutical Industries INC. | $27.02 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.04 | 2024 | Strensiq |
| Antares Pharma, INC. | $20.86 | 2023 | Xyosted, Nocdurna, Tlando |
| Neurocrine Biosciences, INC. | $19.49 | 2025 | |
| Currax Pharmaceuticals LLC | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Grondziowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.